Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Alzheimer's and Dementia

Volumn 13, Issue 3, 2017, Pages 274-284

  Simonsen, Anja Hviid ^a   Herukka, Sanna Kaisa ^b   Andreasen, Niels ^c   Baldeiras, Ines ^d   Bjerke, Maria ^e   Blennow, Kaj ^f   Engelborghs, Sebastiaan ^e,g   Frisoni, Giovanni B ^h,i   Gabryelewicz, Tomasz ^j   Galluzzi, Samantha ⁱ   Handels, Ron ^k   Kramberger, Milica G ^l   Kulczyńska, Agnieszka ^m   Molinuevo, Jose Luis ^n,o   Mroczko, Barbara ^m   Nordberg, Agneta ^p   Oliveira, Catarina Resende ^d   Otto, Markus ^q   Rinne, Juha O ^r   Rot, Uroš ^l   Saka, Esen ^s   Soininen, Hilkka ^b   Struyfs, Hanne ^e   Suardi, Silvia ^t   Visser, Pieter Jelle ^u,v   Winblad, Bengt ^p   Zetterberg, Henrik ^f,w   Waldemar, Gunhild ^a   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g Hospital Network Antwerp (ZNA) Hoge Beuken and Middelheim   (Belgium)

^h UNIVERSITY OF GENEVA   (Switzerland)

ⁱ IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^j MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^m MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o BarcelonaBeta Brain Research Center BBRC   (Spain)

^p KAROLINSKA INSTITUTE   (Sweden)

^q UNIVERSITY OF ULM   (Germany)

^r TURKU UNIVERSITY HOSPITAL   (Finland)

^s HACETTEPE UNIVERSITY   (Turkey)

^t DEPARTMENT OF NEUROSURGERY   (Italy)

^u MAASTRICHT UNIVERSITY   (Netherlands)

^v VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^w UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Biomarkers; CSF; Diagnosis; GRADE; Recommendations

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LABORATORY TEST; LUMBAR PUNCTURE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SYSTEMATIC REVIEW (TOPIC); WELLBEING; BIBLIOGRAPHIC DATABASE; CEREBROSPINAL FLUID; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; DATABASES, BIBLIOGRAPHIC; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 85007289521     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.09.008     Document Type: Short Survey

References (40)

1. [1] American Psychiatric Association. Diagnostic and statistical manual—text revision (DSM-IV-TRim, 2000). 2000, American Psychiatric Association, Arlington, VA.
2. [2] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 2013, American Psychiatric Pub, Arlington, VA.
3. [3] McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
4. [4] Qiu, C., Kivipelto, M., von, S.E., Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11 (2009), 111–128.
5. [5] Karantzoulis, S., Galvin, J.E., Distinguishing Alzheimer's disease from other major forms of dementia. Expert Rev Neurother 11 (2011), 1579–1591.
6. [6] McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
7. [7] Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
8. [8] Hort, J., O'Brien, J.T., Gainotti, G., Pirttila, T., Popescu, B.O., Rektorova, I., et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17 (2010), 1236–1248.
9. [9] Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 19 (2012), 1159–1179.
10. [10] Blennow, K., de Leon, M.J., Zetterberg, H., Alzheimer's disease. Lancet 368 (2006), 387–403.
11. [11] Herukka, S.K., Simonsen, AH, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, et al. Recommendations for the clinical application of CSF biomarkers for Alzheimer's disease in the diagnostic evaluation of patients with mild cognitive impairment. Alzheimers Dement, 2016 In press.
12. [12] Schunemann, H.J., Oxman, A.D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G.E., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008), 1106–1110.
13. [13] Brozek, J.L., Akl, E.A., Jaeschke, R., Lang, D.M., Bossuyt, P., Glasziou, P., et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 64 (2009), 1109–1116.
14. [14] Murphy, M.K., Black, N.A., Lamping, D.L., McKee, C.M., Sanderson, C.F., Askham, J., et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 2 (1998), i–iv 1–88.
15. [15] Leone, M.A., Brainin, M., Boon, P., Pugliatti, M., Keindl, M., Bassetti, C.L., Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2012. Eur J Neurol 20 (2013), 410–419.
16. [16] Handels, R.L., Wolfs, C.A., Aalten, P., Joore, M.A., Verhey, F.R., Severens, J.L., Diagnosing Alzheimer's disease: a systematic review of economic evaluations. Alzheimers Dement 10 (2014), 225–237.
17. [17] Olsson, B., Lautner, R., Andreasson, U., Ohrfelt, A., Portelius, E., Bjerke, M., et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15 (2016), 673–684.
18. [18] Mo, J.A., Lim, J.H., Sul, A.R., Lee, M., Youn, Y.C., Kim, H.J., Cerebrospinal fluid beta-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease—systematic review and meta-analysis. PLoS One, 10, 2015, e0116802.
19. [19] Liu, B., Tang, Y., Shen, Y., Cen, L., Han, M., Cerebrospinal fluid tau protein in differential diagnosis of Alzheimer's disease and vascular dementia in Chinese population: a meta-analysis. Am J Alzheimers Dis Other Demen 29 (2014), 116–122.
20. [20] Rosa, M.I., Perucchi, J., Medeiros, L.R., Fernandes, B., Fernandes Dos Reis, M.E., Silva, B.R., Accuracy of cerebrospinal fluid Abeta(1-42) for Alzheimer's disease diagnosis: a systematic review and meta-analysis. J Alzheimers Dis 40 (2014), 443–454.
21. [21] Ferreira, D., Perestelo-Perez, L., Westman, E., Wahlund, L.O., Sarria, A., Serrano-Aguilar, P., Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Front Aging Neurosci, 6, 2014, 47.
22. [22] Gaugler, J.E., Kane, R.L., Johnston, J.A., Sarsour, K., Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. Am J Alzheimers Dis Other Demen 28 (2013), 337–347.
23. [23] Agarwal, R., Tripathi, C.B., Diagnostic Utility of CSF Tau and Abeta(42) in Dementia: A Meta-Analysis. Int J Alzheimers Dis, 2011, 2011, 503293.
24. [24] Bloudek, L.M., Spackman, D.E., Blankenburg, M., Sullivan, S.D., Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis 26 (2011), 627–645.
25. [25] van Harten, A.C., Kester, M.I., Visser, P.J., Blankenstein, M.A., Pijnenburg, Y.A., van der Flier, W.M., et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49 (2011), 353–366.
26. [26] Mitchell, A.J., CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80 (2009), 966–975.
27. [27] Formichi, P., Battisti, C., Radi, E., Federico, A., Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 208 (2006), 39–46.
28. [28] Sunderland, T., Linker, G., Mirza, N., Putnam, K.T., Friedman, D.L., Kimmel, L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003), 2094–2103.
29. [29] Molinuevo, J.L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret-Liaudet, A., et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 10 (2014), 808–817.
30. [30] Jack, C.R. Jr., PART and SNAP. Acta Neuropathol 128 (2014), 773–776.
31. [31] Rosen, C., Farahmand, B., Skillback, T., Nagga, K., Mattsson, N., Kilander, L., et al. Benchmarking biomarker-based criteria for Alzheimer's disease: data from the Swedish Dementia Registry, SveDem. Alzheimers Dement 11 (2015), 1470–1479.
32. [32] Duits, F.H., Martinez-Lage, P., Paquet, C., Engelborghs, S., Lleo, A., Hausner, L., et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12 (2016), 154–163.
33. [33] Wimo, A., Religa, D., Spangberg, K., Edlund, A.K., Winblad, B., Eriksdotter, M., Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. Int J Geriatr Psychiatry 28 (2013), 1039–1044.
34. [34] Jedenius, E., Wimo, A., Stromqvist, J., Jonsson, L., Andreasen, N., The cost of diagnosing dementia in a community setting. Int J Geriatr Psychiatry 25 (2010), 476–482.
35. [35] van Rossum, I.A., Vos, S., Handels, R., Visser, P.J., Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 20 (2010), 881–891.
36. [36] McMahon, P.M., Araki, S.S., Sandberg, E.A., Neumann, P.J., Gazelle, G.S., Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228 (2003), 515–522.
37. [37] Silverman, D.H., Cummings, J.L., Small, G.W., Gambhir, S.S., Chen, W., Czernin, J., et al. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 4 (2002), 283–293.
38. [38] Moulin-Romsee, G., Maes, A., Silverman, D., Mortelmans, L., Van, L.K., Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neurol 12 (2005), 254–263.
39. [39] Wimo, A., Ballard, C., Brayne, C., Gauthier, S., Handels, R., Jones, R.W., et al. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. J Intern Med 275 (2014), 304–316.
40. [40] Valcarcel-Nazco, C., Perestelo-Perez, L., Molinuevo, J.L., Mar, J., Castilla, I., Serrano-Aguilar, P., Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. J Alzheimers Dis 42 (2014), 777–788.